Renal chronic transplant dysfunction (CTD) is the leading cause of long-term loss of transplanted kidneys. CTD is the result of tissue remodeling in the intrarenal arteries, glomeruli, and tubulointerstitium that leads to transplant vasculopathy, focal glomerulosclerosis (FGS), interstitial fibrosis, and tubular atrophy. These lesions are characterized by accumulation of extracellular matrix, activation of mesangial cells, interstitial myofibroblasts, tubular epithelial cells, and chronic inflammation. To date, in the absence of knowledge of the pathogenetic mechanisms leading to development of these lesions, no effective therapies are available to prevent or treat renal CTD. Progressive loss can only be retarded by antihypertensive and antiproteinuric treatment in combination with lipid-lowering drugs.

Recently, our research group reported accumulation of the heparan sulfate proteoglycans (HSPGs) collagen type XVIII and perlecan during glomerular and vascular tissue remodeling in CTD in rats. However, whether and how these proteoglycans mediate tissue remodeling in CTD is as yet unknown. In native kidney diseases and ischemia–reperfusion injury, we have already demonstrated that HSPGs are involved in...
leukocyte influx and proteinuria-mediated renal injury.\textsuperscript{6–8} Perlecan is a large, modular, pericellular HSPG with a spatial distribution that enables control over major cell-signaling events such as migration, proliferation, and differentiation in response to bound growth factors. Perlecan is composed of five different domains, of which the C-terminal domain, named endorepellin, is best known for its antiangiogenic properties.\textsuperscript{9,10}

The carbohydrate side chains (ie, the glycosaminoglycans) are attached to proteoglycan core proteins and can bind a variety of ligands, depending on their highly variable composition (mainly variations in patterns of N- and O-sulfation).\textsuperscript{11} Along with chondroitin sulfate and dermatan sulfate proteoglycans, HSPGs form the large majority of the proteoglycan family. Potential ligands include chemokines\textsuperscript{11} and growth factors such as basic fibroblast growth factor (bFGF/FGF2).\textsuperscript{12,13} Proteoglycans are highly involved in morphogenesis and in tissue remodeling processes.\textsuperscript{14–19}

Studies in nontransplantation models of renal and vascular disease have identified potential roles of FGF2 in FGS and neointima formation.\textsuperscript{20–24} These findings led us to hypothesize that interaction of FGF2 with proteoglycans also affects tissue remodeling processes in CTD. To test this hypothesis, we used an experimental rat CTD model. We microdissected glomeruli, the arterial media, and the neo-intima and performed low-density quantitative RT-PCR (RT-qPCR) analysis for matrix and cell-surface proteoglycans and FGF2. In addition, we profiled the heparan sulfate (HS) polysaccharide side chains by anti-HS monoclonal antibodies (mAbs) and their binding capacity for FGF2 and L-selectin. Functionally, we investigated the HSPG involvement of FGF2-driven mesangial proliferation. Our data indicate spatial proteoglycan involvement in CTD and thus suggest a potential target for intervention therapy in the future.

**Materials and Methods**

**Rats**

Inbred female Dark Agouti (DA) rats (175 to 210 g) were obtained from Harlan Laboratories (Horst, the Netherlands; Indianapolis, IN) and inbred male Wistar Furth (WF) rats (240 to 295 g) from Charles River Laboratories International (l’Arbresle, France; Wilmington, MA). All animals received care in compliance with the NIH Guide for the Care and Use of Laboratory Animals (revised 1985), the University of Groningen guidelines for animal husbandry, and the Dutch Law on Experimental Animal Care.

**Kidney Transplantation and Experimental Groups**

Female DA kidney allografts were orthotopically transplanted into male Wistar–Furth recipients, as described previously.\textsuperscript{5,25,26} Cold ischemic time ranged from 16 to 38 minutes; warm ischemic time ranged from 19 to 32 minutes. Recipients received 5 mg/kg s.c. cyclosporin A (Sandimmune; Novartis, Basel, Switzerland) on the first 10 days after transplantation. The contralateral kidney was removed 8 to 14 days after transplantation. Total follow-up time was 12 weeks, unless animals had to be sacrificed sooner because of renal failure. Allografts that developed severe CTD were used in this study (n = 5). Further characteristics of the model are described elsewhere.\textsuperscript{5,25,26} Nontransplanted DA kidneys (n = 5) and DA-to-DA isografted kidneys (n = 5) served as controls.

**Laser Microdissection and Gene Expression Analysis**

Laser microdissection, RNA isolation, and RT-qPCR were performed essentially according to Asgeirsdottir et al.\textsuperscript{27} Glomeruli and various layers (including the tunica media and the neointima) of larger arteries were separately dissected from nine serial sections per kidney. An average of 194 (range, 71 to 308) glomeruli and 63 (range, 25 to 117) arteries were dissected from each kidney. Glomeruli and the various arterial layers were isolated from allografted, isografted, and nontransplanted kidneys (n = 5 per group).

Total RNA was also isolated from whole-kidney sections from allograft, isograft, and nontransplanted animals (n = 3 per group). Total RNA was isolated from microdissected structures and whole kidney using an RNeasy micro kit (Qiagen, Hilden, Germany; Valencia, CA). Reverse transcription was performed using Invitrogen SuperScript III Reverse Transcriptase (Life Technologies, Breda, the Netherlands; Carlsbad, CA) and random hexamer primers (Promega, Leiden, the Netherlands; Madison, WI). Gene expression was analyzed with a custom-made microfluidic card–based low-density array (Life Technologies–Applied Biosystems, Nieuwerkerk a/d IJssel, the Netherlands) using an ABI Prism 7900HT sequence detection system (Life Technologies–Applied Biosystems).

Relative mRNA levels were calculated as $2^{-\Delta Ct}$, where $\Delta Ct = C_{T_{\text{gene of interest}}} - C_{T(b-actin)}}$. Ct values that were beyond detection level were set manually to 50. Composition of the low-density array is presented in Table 1.

**Single and Double Immunofluorescence for Proteoglycans and FGF2 on Rat Kidney Sections**

Frozen sections (4 μm thick) were fixed in acetone or 4% formaldehyde and were blocked for endogenous peroxidase activity with 0.03% H2O2 if appropriate. Sections were blocked with normal goat or rabbit serum. Sections were incubated for 1 hour with the following primary antibodies: mouse anti-human FGF2 (PeproTech, London, UK; Rocky Hill, NJ), mouse anti-HS mAb JM-403,\textsuperscript{28} mouse anti-HS stub mAb 3G10 (Seikagaku, Tokyo, Japan),\textsuperscript{29} and mouse anti-rat perlecan (clone 10B2; kindly provided by J.R. Couchman, University of Copenhagen). Binding of primary antibodies was detected by incubating the sections for 30 minutes with secondary antibodies diluted in PBS with 5%
normal rat serum; goat anti-mouse IgG1 horseradish peroxidase (HRP) (Southern Biotech, Birmingham, AL), rabbit anti-mouse IgM HRP (Dako, Heverlee, Belgium; Carpineteria, CA), or goat anti-mouse IgG1 Alexa Flour 488 (Life Technologies). HRP activity was visualized using a tyramide signal amplification tetramethylrhodamine system (TSA; PerkinElmer). Nuclei were counterstained with DAPI. Slides were mounted with Aqua PolyMount medium (Polysciences, Warrington, PA). Images were acquired with an Axio Observer Z1 inverted microscope (Carl Zeiss Microscopy, Jena, Germany) equipped with TissueFAXS acquisition software version 2.0.4 (TissueGnostics, Vienna, Austria; Tarzana, CA).

### Ligand Binding Assays on Rat Kidney Sections

To detect capacity of renal proteoglycans to bind FGF2, formalin-fixed rat renal sections were incubated with 1 μg/mL recombinant human FGF2 (recFGF2; Peprotech) for 60 minutes. After a washing step, staining was continued according to the FGF2 staining protocol as described above. Use of formalin fixation essentially avoids recognition of endogenous renal FGF2 by anti-FGF2 antibodies. Similarly, paraformaldehyde-fixed rat renal sections were incubated with 1 μg/mL L-selectin—Fc recombinant chimeric protein and visualized as described previously. To confirm that the observed binding pattern was mediated by HS proteoglycans, the sections were pretreated with 0.05 U/mL heparitinase I (EC 4.2.2.8, *Flavobacterium heparinum*; Seikagaku) for 1 hour at 37°C in a humidified chamber.

### FGF2 Binding Assays in ELISA

In an enzyme-linked immunosorbent assay (ELISA) approach, we evaluated the capability of fluid phase HS-like polysaccharides to compete for the interaction of recFGF2 with immobilized perlecan. To this end, MaxiSorp 96-well plates (Nalge Nunc International, Rochester, NY) were coated overnight in PBS with 5 μg/mL perlecan (Sigma-Aldrich, St. Louis, MO). After a washing in PBS with 0.05% Tween 20, wells were blocked with 5% nonfat milk powder in Tris-buffered saline for 1 hour. In a separate microtiter plate, 0.5 μg/mL recFGF2 was incubated for 30 minutes with a dilution range of different HS-like polysaccharides and then was transferred to the ELISA plate after the wells had been washed again. Incubation in the wells took 1 hour. The wells were washed again, and monoclonal mouse anti-FGF2 antibodies were added to the wells (0.5 μg/mL Tris-buffered saline—Tween 20). Secondary antibody was added after a washing step (HRP-labeled rabbit anti-mouse IgG, 1:5000; Dako). Secondary antibody was detected with 3,3',5,5'-tetramethylbenzidine substrate (Sigma-Aldrich) for 15 minutes in the dark, and the reaction was stopped by adding 1.5 N H₂SO₄. Absorbance was measured at 450 nm in a microplate reader. All incubations were performed in a volume of 100 μL per well at room temperature. Polysaccharides used in the FGF2 competition ELISA were heparin from porcine intestinal mucosa (Sigma-Aldrich) and HS from bovine kidney (Seikagaku); N-sulfation of HS from bovine kidney and N- and O-desulfation of heparin from porcine intestine were performed as described before. HS from human aorta was

### Table 1 Composition of Low-Density Array

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Protein short name</th>
<th>Gene symbol</th>
<th>Assay ID</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Matrix molecules</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Collagen, type I, alpha 1</td>
<td>Collagen I</td>
<td>Col1a1</td>
<td>Rn01463848_m1</td>
</tr>
<tr>
<td>Collagen, type IV, alpha 1</td>
<td>Collagen IV</td>
<td>Col4a1</td>
<td>Rn01482925_m1</td>
</tr>
<tr>
<td><strong>Proteoglycans</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perlecan</td>
<td>Perlecan</td>
<td>LOC513641</td>
<td>Rn01515780_g1</td>
</tr>
<tr>
<td>Agrin</td>
<td>Agrin</td>
<td>Agm</td>
<td>Rn00598349_m1</td>
</tr>
<tr>
<td>Versican</td>
<td>Versican</td>
<td>Vcan</td>
<td>Rn01493755_m1</td>
</tr>
<tr>
<td>Biglycan</td>
<td>Biglycan</td>
<td>Bgn</td>
<td>Rn00567229_m1</td>
</tr>
<tr>
<td>Syndecan 1</td>
<td>Syndecan-1</td>
<td>Sdc1</td>
<td>Rn00564662_m1</td>
</tr>
<tr>
<td>Syndecan 4</td>
<td>Syndecan-4</td>
<td>Sdc4</td>
<td>Rn00561900_m1</td>
</tr>
<tr>
<td><strong>Growth factors</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibroblast growth factor 2</td>
<td>FGF2</td>
<td>Fgf2</td>
<td>Rn00570809_m1</td>
</tr>
<tr>
<td>Transforming growth factor, beta 1</td>
<td>TGF-b1</td>
<td>Tgfb1</td>
<td>Rn01475963_m1</td>
</tr>
<tr>
<td><strong>Reference genes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Beta actin</td>
<td>β-Actin</td>
<td>Actb</td>
<td>Rn00667869_m1</td>
</tr>
<tr>
<td>Beta 2 microglobulin</td>
<td>B2M</td>
<td>B2m</td>
<td>Rn00560865_m1</td>
</tr>
<tr>
<td>Eukaryotic 18S rRNA</td>
<td>18S</td>
<td>18S</td>
<td>Hs99999901_s1</td>
</tr>
</tbody>
</table>
isolated essentially according to the method of Iverius. HS from Engelbreth-Holm-Swarm murine sarcoma was obtained from Seikagaku.

To evaluate FGF2 binding by perlecan from renal lysates, a slightly modified ELISA approach was followed. Perlecan from renal lysates (10 µg protein/mL carbonate buffer) was immunocaptured on monoclonal mouse anti-rat perlecan antibody (1:1000 in PBS; mAb 10B2; provided by J.R. Couchman) immobilized in MaxiSorp 96-well plates. After appropriate blocking, captured renal perlecan was incubated with 0.5 µg/mL recFGF2, followed by biotinylated anti-FGF2 mAb (clone JKFb-2, 1 µg/mL Tris-buffered saline—TWEEN 20; Novus Biologicals, Cambridge, UK) and then by HRP-conjugated streptavidin (1:5000 in Tris-buffered saline—TWEEN 20). Substrate reaction and plate reading was as described above.

**FGF2 Stimulation Assay on Rat Mesangial Cells**

Rat mesangial cells (positive for Thy 1.1, perlecan, and α-smooth muscle actin; passage 11 to 15) were cultured in 24-well plates in Dulbecco’s modified Eagle’s medium supplemented with 25 mmol/L HEPES, 4.5 mg/mL glucose, pyridoxine, 1 mmol/L pyruvate, 50 ng/mL insulin, and 10% fetal bovine serum. Before stimulation with FGF2, cells were grown until confluency, serum-deprived (0.5% serum) for 24 hours, and then incubated with 0.031 to 8 ng/mL of FGF2 for 24 hours. For measurement of proliferation, 0.5 µCi/mL [3H]thymidine (GE Healthcare) was added to the cultures. After 24 hours, 5% trichloroacetic acid precipitable material was dissolved in 0.1% SDS, OptiPhase HiSafe 3 liquid scintillation cocktail (PerkinElmer) was added, and radioactivity was counted in a Wallac 1214 Rackbeta liquid scintillation counter (PerkinElmer). To study whether FGF2-induced proliferation of mesangial cells was reduced in the presence of exogenous HS, mesangial cells were stimulated with 0.5 ng/mL FGF2 for 24 hours in the presence of various concentrations (0, 8, 32, and 128 µg/mL) of exogenous HS from bovine kidney (HSBK; Seikagaku). Proliferation was measured as described above.

To study whether proteoglycan sulfation was reduced by chlorate, mesangial cells were cultured for 24 hours in the presence of 5 to 25 mmol/L sodium chlorate (Sigma-Aldrich) and 2 µCi/mL [35S]sulfate (GE Healthcare, Little Chalfont, UK). Incorporation of [35S]sulfate into proteoglycans was quantified as described above for [3H]thymidine incorporation. Finally, to analyze whether chlorate impairs FGF2-induced proliferation of mesangial cells, cells

![Figure 1](https://example.com/figure1.png)
were stimulated with 0.5 ng/mL FGF2 for fixed times (0, 0.5, 1, 2, 4, and 24 hours) in the presence or absence of 25 mmol/L sodium chlorate and in the presence of 0.5 μCi/mL [3H]thymidine. Total culture time was 24 hours. Proliferation was determined as described above. Before stimulation with FGF2, cells were grown until confluency, serum-deprived (0.5% serum) for 24 hours, and incubated with FGF2 for 24 hours. Proliferation was measured by adding 0.5 μCi/mL [3H]thymidine (GE Healthcare) for 24 hours to the cultures. After 24 hours, 5% trichloroacetic acid precipitable material was dissolved in 0.1% SDS, OptiPhase HiSafe 3 cocktail (PerkinElmer) was added, and radioactivity was counted in a Wallac 1214 Rackbeta liquid scintillation counter (PerkinElmer). Incorporation of [35S]sulfate into proteoglycans was quantified similarly as described above for [3H]thymidine incorporation.

Detection of Perlecan Expression on Proliferating Rat Mesangial Cells

Rat mesangial cells were cultured as described above. After expansion, cells were seeded on coverslips and serum-starved for 24 hours in medium containing 0.5% fetal calf serum (FCS) after attachment. Subsequently, cells were stimulated for 48 hours in medium containing either 2% or 10% FCS. After stimulation, cells were fixed in 2% paraformaldehyde and double-stained for α-SMA (mIgG2a, clone 1A4; Dako) and perlecan (mIgG1, clone 10B2) as described above. Binding of primary antibodies was detected by incubating the sections for 30 minutes with goat anti-mouse IgG1 Alexa Fluor 488 and goat anti-mouse IgG2a, Alexa Fluor 555 (Life Technologies). Nuclei were counterstained with DAPI. Slides were mounted with Aqua PolyMount medium (Polysciences). Confocal microscopy was performed using an inverted microscope (Zeiss LSM 780 NLO; Axio Observer Z1). To quantify total cell numbers and numbers of perlecan expressing mesangial cells, coverslips were scanned using TissueFAXS acquisition software (TissueGnostics) on a Zeiss Axio Observer Z1 inverted microscope. Quantitative analyses were performed using TissueQuest fluorescence analysis software (TissueGnostics).

Statistical Analysis

mRNA expression levels were analyzed using a one-way analysis of variance with Tukey’s post hoc test. P values of <0.05 were considered statistically significant (IBM SPSS software version 18; IBM, Armonk, NY). Statistical outliers, as detected by Grubbs’ test for outliers, were excluded from analyses. Mesangial cell culture data were expressed as means ± SEM and analyzed by one-way analysis of variance. If overall $P < 0.05$, Bonferroni’s
multiple comparison test was performed (GraphPad Prism version 5.0; GraphPad Software, San Diego, CA).

Results

Development of Chronic Transplant Dysfunction in Renal Allografts

Progressive renal function loss was evidenced in the allografted kidneys by an approximately 50% loss in creatinine clearance and an approximately 15-fold increase in urinary protein excretion at 8 weeks after transplantation, neither of which was observed in isografted kidneys, as we have previously shown in this model.5,25,26 Allografted rats developed hypertension and showed development of severe CTD with FGS (Figure 1A) and arterial neointima formation (Figure 1B). In isografts, development of FGS was minimal and no neointima formation was observed.5,25,26 The development of FGS coincided with significantly increased expression of the profibrotic factors collagen type I (ColIα1), collagen type IV (ColIVα1), and transforming growth factor β1 (TGF-β1), as determined by RT-qPCR on microdissected glomeruli (Figure 1C). These molecular responses were also observed in RNA isolated from microdissected arterial medial and neointimal tissue, as well as in whole-kidney material.26 These findings confirm development of CTD in our rat transplantation model.

Induction of Glomerular and Neointimal Perlecan Expression in CTD

Proteoglycans can modulate growth factor responses by virtue of their glycosaminoglycan side chains. We used RT-qPCR to profile the matrix HS proteoglycans agrin and

Table 2  Basic Characteristics of the HS Epitopes Recognized by the Two Anti-HS mAbs, FGF2, and L-selectin

<table>
<thead>
<tr>
<th>Anti-HS mAb or HS-binding protein</th>
<th>Basic characteristics of the HS epitope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-HS mAb JM-403</td>
<td>GlcUA-rich sequences with N-unsubstituted GlcN units in low sulfated HS28</td>
</tr>
<tr>
<td>Anti-HS mAb 3G10</td>
<td>Desaturated uronate residues after digestion with heparitinase (GlcNAc/NS α1-4 GlcA linkage29)</td>
</tr>
<tr>
<td>FGF2</td>
<td>2-O-sulfation in heparin and HS32</td>
</tr>
<tr>
<td>L-selectin</td>
<td>6-O-sulfated GlcN units in HS and heparin33</td>
</tr>
</tbody>
</table>

Figure 3   Modification of glomerular HS structure in allografts with CTD. Glomerular expression of HS was evaluated by two anti-HS mAbs, JM-403 (A) and 3G10 (B), as well as by binding of FGF2 (C) and L-selectin (D). In allografts, glomerular JM-403 staining (A) is partly lost in sclerotic areas (arrows), as evidenced by loss of JM-403 staining (brown) in PAS-positive sclerotic area. In contrast, HS expression as evidenced by 3G10 (B) and FGF2 binding capacity (C) is increased in glomeruli in allografts. L-selectin (D) does not bind to glomerular HS of control, isografted, or allografted kidneys, although HS binds L-selectin in Bowman's capsule and in tubular basement membranes. Blanks (PBS control) show staining of allograft renal tissue without anti-HS mAb (A and B) or ligand binding assay without incubation with FGF2 (C) or L-selectin (D); double-staining with DAPI (blue) is used to visualize the nuclei of renal material. Bowman’s capsule is marked by a dotted line (A). Scale bar = 50 μm.
perlecan, the matrix chondroitin sulfate and dermatan sulfate proteoglycans versican and biglycan, and the major epithelial cell-surface proteoglycans syndecan-1 and -4. The PCR analysis showed the expression of the basement membrane HSPG perlecan to be up-regulated mainly in the glomeruli (Figure 2A) and the mediae and neointimae (Figure 2B) of the allografts. However, the localized up-regulation of perlecan revealed by RT-qPCR in glomeruli, mediae, and neointimae was not observed with RT-qPCR analysis performed on whole-kidney RNA isolates (Figure 2C), which points to the need for using microdissection of specific structures to demonstrate differential proteoglycan expression in specific renal compartments.

Use of immunofluorescence revealed that expression of perlecan was virtually absent in the glomerular basement membranes of nontransplanted control kidneys. In the glomerular basement membranes of isografts, perlecan expression was increased, compared with control kidneys, but to a far lesser extent than the increase observed in allografts (Figure 2D). In glomeruli with FGS in allografts, strong expression of perlecan was observed in the glomerular basement membranes and mesangial areas (Figure 2D). In control tissue isografts and allografts, Bowman’s capsule was positive for perlecan. Immunofluorescence also revealed perlecan expression in the mediae and in the newly formed neointimae present in allografts (Figure 2D). Quantification of glomerular perlecan expression by digital image analysis (ImageJ version 1.48b; NIH, Bethesda, MD) revealed a significant increase in perlecan expression in the glomeruli of allografted kidneys, compared with isografts (P < 0.01) and nontransplanted kidneys (P < 0.01) (Figure 2E).

No significant differences in expression levels were found for syndecan-1 and -4, agrin, and biglycan, although these proteoglycans were expressed in the neointimae based on RT-qPCR data (Supplemental Figure S1). Versican expression was significantly up-regulated in the media of the allografted kidneys (Supplemental Figure S1E), which consistent with a promigratory phenotype of the vascular smooth muscle cells. This proteoglycan profiling led us to conclude that glomerular and neointimal perlecan is up-regulated in renal allografts at both the mRNA and the protein level.

HS Profiling

Because HS proteoglycans are involved in morphogenesis and tissue remodeling mainly by their HS glycosaminoglycan side chains, we profiled HS polysaccharide structures in renal sections. To this end, we visualized HS epitopes with anti-HS mAbs JM-403 and 3G10 and with a tissue ligand binding assay using the HS-binding growth factor FGF2 and HS-binding adhesion molecule L-selectin. Characteristics of the corresponding HS epitopes are presented in Table 2.

Anti-HS mAb JM-403 showed clear staining of the glomerular basement membranes in control and isografted kidneys (Figure 3A). Mesangial staining was weak for mAb JM-403. In allografts, however, glomerular JM-403 HS staining was partly or completely lost in sclerotic areas (Figure 3A), likely because of increased HS sulfation. PAS-positive sclerotic tissue was negative for anti-HS mAb JM-403. The 3G10 HS epitope, which becomes available after
heparitinase cleavage of HS, was absent in the glomerular basement membranes of control kidneys, became weakly expressed in the isografted kidneys, and was strongly upregulated in glomerular basement membranes and sclerotic areas in the allografts (Figure 3B). The 3G10 staining showed colocalization with perlecan (Figure 4), which might suggest expression by perlecan. FGF-2 binding was completely HS-dependent, as evidenced by control experiments on sections pretreated with heparitinase, in which all binding of FGF-2 was lost (data not shown). In glomeruli of control kidneys and isografts, FGF-2 binding to HS was absent or only weakly present, but increased binding of FGF-2 was observed in allografts (Figure 3C). Although L-selectin clearly bound to HS in Bowman’s capsule and to HS in a number of tubular basement membranes, no glomerular staining was observed in control, isografted, or allografted kidneys (Figure 3D).

In the arterial media of control and isografted kidneys, moderate staining for anti-HS mAbs JM-403 and 3G10 was observed (Figure 5, A and B); however, binding capacity for FGF2 and L-selectin was absent (Figure 5, C and D). In contrast to staining in the mediae of control and isografted kidneys, JM-403 staining was lost in allograft mediae, but 3G10 staining was increased (Figure 5, A and B). Moreover, FGF2 binding capacity was increased in the allograft mediae (Figure 5C). In the neointima, strong binding of anti-HS mAbs JM-403 and 3G10 was observed, as well as binding of FGF2 (Figure 5, A–C). L-selectin did not bind to arterial HS of control, isografted, or allografted kidneys (Figure 5D), despite recognition of HS isoforms in other renal structures, such as Bowman’s capsule and tubular basement membranes (Figure 3).

Taken together, these findings indicate changes in glomerular and arterial HS composition in allografts with CTD, loss of JM-403 staining, and increased FGF2 binding capacity, without L-selectin binding capacity. Based on the epitope requirements (Table 2), this can be explained by increased HS sulfation (most likely N-sulfation and 2-O-sulfation, but not 6-O-sulfation).

FGF2 Binding to Perlecan HS Requires Specific Sulfation Motifs

In an ELISA approach, we evaluated the interaction of recFGF2 with immobilized perlecan and studied competition of FGF2–perlecan interaction by fluid phase glycosaminoglycans. As expected, heparin dose-dependently inhibited the interaction of FGF2 with the HS side chains of perlecan. N-desulfation of heparin largely reduced the inhibitory capacity of heparin, and O-desulfation completely prevented interaction with FGF2 (Figure 6A). Dose-dependent inhibition was also achieved by HS isolated from bovine kidney, although to a lesser extent than heparin. N-deacetylation followed by N-resulfation of HS isolated from bovine kidney increased the inhibitory capacity (Figure 6B), whereas low-sulfated HS from mouse EHS tumor or from human aorta inhibited FGF2–perlecan interaction only to some extent or not at all. These findings
show that the degree of sulfation of HS and heparin polysaccharides determines interaction with FGF2.

Next, we evaluated the FGF2 binding capacity of perlecan selectively adsorbed from renal lysates by immobilized anti-rat perlecan mAb in ELISA plates. Perlecan from allografted kidneys bound substantially more FGF2, compared with perlecan from control kidneys \((P < 0.01)\) (Figure 6C), because of increased sulfation and/or content of perlecan from allografted kidneys.

**Endogenous Expression of FGF2 in Allografts with CTD**

We next evaluated endogenous expression levels of FGF2. In control kidneys, we observed only weak segmental FGF2

![Figure 6](image_url) FGF2 binding to perlecan. A and B: Inhibition of the binding of recFGF2 to immobilized perlecan by fluid-phase GAGs was measured by ELISA. Heparin dose-dependently inhibits FGF2 from binding to immobilized perlecan. N-desulfated heparin largely loses inhibitory capacity and O-desulfated heparin completely loses binding to FGF2 (A). HS from bovine kidney dose-dependently inhibits FGF2 binding to perlecan (B). N-sulfated HS from bovine kidney increases binding capacity to FGF2. In contrast, two less sulfated HS preparations (from EHS sarcoma and human aorta) bind poorly with FGF2. C: FGF2 binding to antibody-captured perlecan from renal lysates indicates increased FGF2 binding to perlecan from allografted kidneys, compared with perlecan from control kidneys. Data are expressed as means \(\pm\) SEM (C). **\(P < 0.01\).

![Figure 7](image_url) Glomerular and arterial expression of FGF2 in allografts with CTD. Endogenous expression of FGF2 is evaluated by immunofluorescence (A and B) and RT-qPCR (C and D). In allografts with CTD, a strong expression of FGF2 is exclusively found in glomeruli (A) and neointimae (B). In glomeruli of isografts, a slight increase in FGF2 expression is found (A). The internal elastic lamina is marked by a dotted line. C: Quantification of glomerular FGF2 expression by digital image analysis shows significant increase in allografted kidneys (left). RT-qPCR analysis revealed no increase in FGF2 expression in the glomeruli in allografts, compared with isografts and nontransplanted control tissue (right). D: Neointimal expression of FGF2. The blank (PBS control) was stained without incubation by anti-FGF2 mAb, in the presence of DAPI to show the nuclei of renal allograft tissue. Data are expressed as means \(\pm\) SEM. **\(P < 0.01\), ***\(P < 0.001\). \(n = 5\) per group. Scale bar = 50 \(\mu m\).
expression in the glomeruli and the tubulointerstitium (Figure 7A). Arteries were devoid of any FGF2 expression (Figure 7B). In isografts, a slight up-regulation of FGF2 expression in glomeruli was observed, with the arteries remaining devoid of any FGF2 expression (Figure 7, A and B). In the allografts, however, FGF2 was strongly and homogeneously accumulated throughout the glomeruli and was present mainly in the glomerular capillary wall and mesangium (Figure 7A). Quantification of FGF2 staining by digital image analysis revealed strong increased FGF2 expression in the glomeruli of allografted kidneys, compared with isografted kidneys ($P < 0.02$) and non-transplanted control kidneys ($P < 0.01$) (Figure 7C). PCR analysis revealed no significant differences in glomerular FGF2 expression, although a tendency toward higher expression was observed in the allografts (Figure 7C). We suggest that this discrepancy may be explained by plasma-derived FGF2 being trapped in the glomeruli by perlecan endowed with HS chains able to bind FGF2 (Figure 3) during ultrafiltration; this would cause local accumulation of FGF2 protein in the absence of any increase in mRNA expression. In the neointima of allografts, increased FGF2 expression was observed at the protein level, but not at the mRNA level (Figure 7, B and D).

Involvement of Proteoglycans in FGF2-Driven Proliferation of Mesangial Cells

To explore a possible mechanistic relation between glomerular HSPGs and FGF2 in greater detail, we conducted in vitro experiments. Primary rat mesangial cells were cultured and stained for $\alpha$-smooth muscle actin and perlecan. A confocal image of cultured mesangial cells stained for $\alpha$-smooth muscle actin (activation marker of mesangial cells) and perlecan reveals that activated, proliferating mesangial cells express perlecan, and magnification of a Z-stack compilation clearly demonstrated the extracellular presence of perlecan positioned on the cell membrane (Figure 8A). We next compared perlecan expression in resting (2% FCS culture conditions) and proliferating (10% FCS) mesangial cell cultures, presented as tissue fluorescence-activated cell-sorting scatter plots (B) and as quantification of the data (C). 10% FCS induces significant proliferation of the mesangial cells, with an increase in the absolute numbers of perlecan-positive mesangial cells. Relatively, the percentage of perlecan-positive cells is decreased after culturing with 10% FCS, compared with 2% FCS. Data are expressed as means ± SEM (C). *$P < 0.05$, **$P < 0.01$. Scale bar = 20 $\mu$m.

Figure 8 Proliferating mesangial cells express perlecan on their cell membranes. A: Proliferating rat mesangial cells were double-stained for $\alpha$-smooth muscle actin and perlecan to show perlecan expression on the cell membranes of proliferating mesangial cells. The boxed region is shown at higher magnification in the right image. The image is a compressed confocal Z-scan of 2.63 $\mu$m consisting of seven stacks. B and C: Comparison of cell numbers (based on DAPI staining) and perlecan expression (Alexa Fluor 488) in resting (2% FCS) and proliferating (10% FCS) mesangial cell cultures, presented as tissue fluorescence-activated cell-sorting scatter plots (B) and as quantification of the data (C). 10% FCS induces significant proliferation of the mesangial cells, with an increase in the absolute numbers of perlecan-positive mesangial cells. Relatively, the percentage of perlecan-positive cells is decreased after culturing with 10% FCS, compared with 2% FCS. Data are expressed as means ± SEM (C). *$P < 0.05$, **$P < 0.01$. Scale bar = 20 $\mu$m.
a proliferation marker. In allografted kidneys, but not in isografted and nontransplant control kidneys, the number of Ki-67-positive nuclei was increased in Thy-1-positive mesangial areas within the glomeruli (Figure 9B). Perlecan expression in the same kidneys demonstrated that mesangial proliferation associates with increased perlecan in the same allografts (Figure 9A).

We observed a dose-dependent increase in proliferation of mesangial cells in response to FGF2 (Figure 10A). The FGF2-induced proliferative response was blunted by the addition of exogenous competitive bovine kidney-derived HS (Figure 10B), because of reduced binding of FGF2 to the cells, as demonstrated by reduced binding of 125I-labeled FGF2 to the mesangial cells (data not shown). To verify that proliferation of the mesangial cells is dependent on FGF2 binding by endogenous HS, cells were cultured in the presence of chlorate, which inhibited the sulfation of the side chains of the proteoglycans in a dose-dependent manner (Figure 10C). Chlorate prevented the FGF2-induced proliferative response of mesangial cells, which appeared to be dependent on the duration of FGF2 stimulation (Figure 10D). These results indicate that the proliferation of mesangial cells is dependent on FGF2 binding to endogenous HS proteoglycans such as perlecan. The interaction between FGF2 and HS proteoglycans on mesangial cells may therefore play a key role in the development of FGS.

Discussion

Here we have provided evidence that matrix HSPGs such as perlecan serve as functional docking platforms for FGF2 and contribute to glomerular and arterial tissue remodeling in experimental CTD. The concept of extracellular regulation of growth factors by proteoglycans has been studied predominantly in tissue remodeling related to embryonic development,14,15 ontogenesis,16,17 and angiogenesis.18,19 The present results indicate that HSPGs modulate growth factors in the renal transplant setting as well. This important finding opens the possibility of targeting proteoglycans by therapeutic intervention to ameliorate the development of CTD.

Development of CTD in renal allografts is the result of tissue remodeling that affects all functional and structural compartments of the kidney, including the tubulointerstitium (tubular atrophy and interstitial fibrosis), glomeruli (focal glomerulosclerosis), and larger arteries (neointima formation).2–4 We previously demonstrated compositional changes of the HSPGs collagen type XVIII, perlecan, and agrin in tissue remodeling in experimental CTD by immunofluorescence.5 We investigated functional aspects of proteoglycans in experimental CTD and in renal cell culture assays. Depending on their highly variable composition, HS carbohydrate side chains can bind a variety of ligands,
observed in glomeruli of allografted kidneys suggests a role in the proliferative response of mesangial cells, which was substantiated by the finding of Ki-67—positive nuclei within Thy-1—positive mesangial cells in allografted kidneys. In other settings, perlecan and FGF2 have been shown to induce proliferation in a number of cell types, including chondrocytes, neural stem cells, retinal pigment epithelial cells, and vascular smooth muscle cells.19,35—37

In the kidney, FGF2 has been shown to be proliferative for fibroblasts and mesangial cells.38,39 In vitro studies showed that the expression of cell-surface HSPG was a prerequisite for the proliferation of renal fibroblasts in response to FGF2.39 We therefore examined the functional role of the FGF2—proteoglycan interaction in mesangial cell proliferation in vitro. FGF2 was shown to induce mesangial cell proliferation in a dose- and sulfation-dependent manner, which favors a role for the FGF2—proteoglycan interaction in mesangial cell proliferation. The exact mechanism by which HSPGs enhance FGF2-induced mesangial cell proliferation is unknown. We propose that binding of FGF2 to mesangial (matrix) HSPGs such as perlecan facilitates the interaction between FGF2 and its surface receptor on mesangial cells, as has been demonstrated for other cell types.35—40 This is supported by our observation that removing the FGF2 binding capacity of proteoglycans on mesangial cells by chlorate treatment resulted in a significant delay in (but not complete abrogation of) FGF2-induced proliferation. In a separate series of experiments, we excluded a direct effect of perlecan on a fibrogenic response (RT-qPCR for ColIα1, ColIVα1, and TGF-β1) by the mesangial cells (data not shown).

Based on our data, HSPGs could hold promise as therapeutic targets to limit CTD, especially focused on the potential of inhibiting growth factor signaling. Addressing the possibility that exogenous glycosaminoglycans may hamper growth factor responses, heparin and heparinoids have been shown to reduce progressive renal failure in experimental renal diseases, including renal transplantation.31—33 Increasingly, research interest is focusing on the possibility of producing small HS mimetics, which may more specifically target a particular component of HS and heparin bioactivity.44 The use of HSPGs as targets (for example, using antibodies that recognize and thereby block specific HS motifs or domains) may also have clinical potential. This strategy has been exemplified in vitro by the demonstration that 6-O-sulfate—specific anti-HS antibodies produced in a phase-display library can inhibit leukocyte rolling and firm adhesion to glomerular endothelial cells, whereas anti-HS antibodies with different specificities do not.35 Mutant growth factors that are rendered incapable of glycosaminoglycan binding could be used to specifically inhibit cell survival and/or proliferation. In addition, small inactive growth factor fragments could be generated that block the HSPG-binding sites of their active counterparts. Thus, there are various options for the use of HSPGs in therapeutic strategies, but further proof of efficacy in vivo needs to be provided.
Acknowledgments

We thank Peter Zwiers, Marian Bulthuis, André Zandvoort, and Annemieke Smit-van Oosten for their excellent technical assistance.

Supplemental Data

Supplemental material for this article can be found at http://dx.doi.org/10.1016/fj.ajpath.2013.07.030.

References


40. Strutz F: The role of FGF-2 in renal fibrogenesis. Front Biosci (Schol Ed) 2009, 1:125–131


